Maxwell D Leslie
Overview
Explore the profile of Maxwell D Leslie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
209
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huber A, Michailidis E, Tang J, Puray-Chavez M, Boftsi M, Wolf J, et al.
Antimicrob Agents Chemother
. 2017 Mar;
61(6).
PMID: 28320718
Hepatitis B virus (HBV) RNase H (RNH) is an appealing therapeutic target due to its essential role in viral replication. RNH inhibitors (RNHIs) could help to more effectively control HBV...
2.
Michailidis E, Huber A, Ryan E, Ong Y, Leslie M, Matzek K, et al.
J Biol Chem
. 2014 Jun;
289(35):24533-48.
PMID: 24970894
4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) is a nucleoside analog that, unlike approved anti-human immunodeficiency virus type 1 (HIV-1) nucleoside reverse transcriptase inhibitors, has a 3'-OH and exhibits remarkable potency against wild-type and drug-resistant...
3.
Huber A, Michailidis E, Schultz M, Ong Y, Bloch N, Puray-Chavez M, et al.
Antimicrob Agents Chemother
. 2014 May;
58(8):4915-9.
PMID: 24867973
Sterile alpha motif- and histidine/aspartic acid domain-containing protein 1 (SAMHD1) limits HIV-1 replication by hydrolyzing deoxynucleoside triphosphates (dNTPs) necessary for reverse transcription. Nucleoside reverse transcriptase inhibitors (NRTIs) are components of...
4.
Kirby K, Michailidis E, Fetterly T, Steinbach M, Singh K, Marchand B, et al.
Antimicrob Agents Chemother
. 2013 Oct;
57(12):6254-64.
PMID: 24100493
Nucleos(t)ide reverse transcriptase inhibitors (NRTIs) form the backbone of most anti-HIV therapies. We have shown that 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) is a highly effective NRTI; however, the reasons for the potent antiviral...
5.
Michailidis E, Ryan E, Hachiya A, Kirby K, Marchand B, Leslie M, et al.
Retrovirology
. 2013 Jun;
10:65.
PMID: 23800377
Background: The K65R substitution in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) is the major resistance mutation selected in patients treated with first-line antiretroviral tenofovir disoproxil fumarate (TDF)....
6.
Hachiya A, Reeve A, Marchand B, Michailidis E, Ong Y, Kirby K, et al.
Antimicrob Agents Chemother
. 2013 Jun;
57(9):4554-4558.
PMID: 23796932
Drug combination studies of 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) with FDA-approved drugs were evaluated by two different methods, MacSynergy II and CalcuSyn. Most of the combinations, including the combination of the two adenosine...
7.
Singh K, Marchand B, Rai D, Sharma B, Michailidis E, Ryan E, et al.
J Biol Chem
. 2012 Sep;
287(45):38110-23.
PMID: 22955279
Rilpivirine (RPV) is a second generation nonnucleoside reverse transcriptase (RT) inhibitor (NNRTI) that efficiently inhibits HIV-1 resistant to first generation NNRTIs. Virological failure during therapy with RPV and emtricitabine is...
8.
Kirby K, Marchand B, Ong Y, Ndongwe T, Hachiya A, Michailidis E, et al.
Antimicrob Agents Chemother
. 2012 Jan;
56(4):2048-61.
PMID: 22252812
RNase H inhibitors (RNHIs) have gained attention as potential HIV-1 therapeutics. Although several RNHIs have been studied in the context of HIV-1 reverse transcriptase (RT) RNase H, there is no...
9.
Durk R, Singh K, Cornelison C, Rai D, Matzek K, Leslie M, et al.
PLoS One
. 2011 Jan;
5(12):e15049.
PMID: 21203539
Background: Foot-and-Mouth Disease Virus (FMDV) is a picornavirus that infects cloven-hoofed animals and leads to severe losses in livestock production. In the case of an FMD outbreak, emergency vaccination requires...